kabutan
About Information Provided on This Site

The information provided on our website 'Kabutan.com' is not intended to constitute investment solicitation or investment advisory services.
All investment decisions should be made at your own discretion and judgment.
The data on our website is provided by Tokyo Stock Exchange, Osaka Exchange, Nagoya Securities Exchange, JPX Market Innovation & Research, Japannext, and other sources.
Copyright of the Nikkei Stock Average belongs to Nikkei Inc. Stock price charts displayed on Kabutan.com are provided solely for the purpose of reviewing historical price movements of the securities.
These charts neither suggest nor guarantee future price movements of the securities and do not constitute recommendations to buy or sell.
In our financial results coverage, the term 'Surprise Results' identifies securities that demonstrate a significant degree of surprise in their earnings announcements.
This significance is quantitatively assessed based on multiple factors, including: the nature of the announcement (full-year or quarterly results); types of revisions (earnings or dividend forecasts); and numerical analysis comparing the announced results with both the company's previous forecasts and historical performance.
The 'Surprise Ranking' presents these results in order of their calculated surprise factor. Please note that neither these results nor rankings are intended to suggest or guarantee future performance of the listed securities, nor should they be construed as recommendations to buy or sell.
minkabu the infonoid
(C) 2024 MINKABU THE INFONOID, Inc.
kabutan

Medix Inc.(331A) Financial Results

331A
TSE Standard
Medix Inc.
492
JPY
-68
(-12.14%)
Apr 7, 3:30 pm JST
3.37
USD
Apr 7, 2:30 am EDT
Result
PTS
outside of trading hours
530
Apr 7, 11:02 pm JST
Summary Chart Historical News Financial Result
Current Period Guidance
Annual
Result
Guidance History
Growth Rate
Profitability
Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Mar, 2021 ＊ 11,979 ー 123 -117 -16.4 0 ー J-GAAP
Mar, 2022 ＊ 14,392 ー 516 134 18.2 3.80 ー J-GAAP
Mar, 2023 ＊ 4,273 784 815 401 53.0 6 ー J-GAAP
Mar, 2024 ＊ 4,179 801 804 489 64.9 8 ー J-GAAP
Mar, 2025 Guidance 4,185 810 957 812 101.1 14 Mar 19, 2025 J-GAAP
YoY +0.1% +1.1% +19.0% +66.1% +55.9%
All-Time High
Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS
Record 15,439 801 815 489 64.9
Fiscal Year Mar, 2020 Mar, 2024 Mar, 2023 Mar, 2024 Mar, 2024
Second Half
Cash Flow
Annual
Fiscal Year Operating Profit Fee Cash Flow Operating Cash Flow Investing Cash Flow Financial Cash Flow Cash & Equivalents Cash Ratio Accounting Standards
Mar, 2023 784 585 557 28 0 2,313 42.59 J-GAAP
Mar, 2024 801 683 675 8 -217 2,780 47.09 J-GAAP
Actual Performance and Financial Trends
Accumulated Results 3rd Quarter
Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Progress Rate vs. First Half Announce Accounting Standards
Apr - Dec, 2024 2,997 499 646 596 79.3 67.5 Mar 19, 2025 J-GAAP
YoY － － － － －
Quarterly Results
Result
Growth Rate
Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Operating Profit Margin Announce Accounting Standards
Oct - Dec, 2024 1,053 246 246 161 21.4 23.4 Mar 19, 2025 J-GAAP
YoY － － － － －
All-Time High Quarterly Results
Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS
Record 1,053 246 246 161 21.4
Fiscal Year Dec, 2024 Dec, 2024 Dec, 2024 Dec, 2024 Dec, 2024
Key Balance Sheet Figures
Fiscal Year BPS Equity Ratio Total Asset Equity Retained Earnings Interest-Bearing Debt Ratio Announce Accounting Standards
Mar, 2022 8,944.24 26.4 5,137 1,355 ー ー ー J-GAAP
Mar, 2023 11,410.00 31.8 5,431 1,729 ー ー ー J-GAAP
Mar, 2024 14,324.00 36.5 5,903 2,157 ー ー ー J-GAAP
Apr - Dec, 2024 ー 44.9 5,994 2,693 2,555 0.06 Mar 19, 2025 J-GAAP